Epirubicin

Leiomyosarcoma

EpkinPhase 1Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 89/ 100

Competitive context

15 Active assets in the Leiomyosarcoma cohort.

Asset / Sponsor	Phase	Rating
vx-970 Massachusetts General Hospital	Phase 2	B
Cediranib University Health Network, Toronto	Phase 2	CCC
Tabelecleucel Pierre Fabre Medicament	Phase 2	CCC
Durvalumab University Health Network, Toronto	Phase 2	CCC
Nivolumab Instituto do Cancer do Estado de São Paulo	Phase 2	CCC

View all 19 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.